Adverum Biotechnologies, Inc.
ADVM
$2.93
-$0.05-1.68%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -130.93M | -99.06M | -104.81M | -117.85M | -122.12M |
| Total Depreciation and Amortization | 3.65M | 3.85M | 4.47M | 5.05M | 5.64M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 33.90M | 21.56M | 28.45M | 33.35M | 34.08M |
| Change in Net Operating Assets | 911.00K | -11.89M | -16.43M | -12.29M | -8.51M |
| Cash from Operations | -92.46M | -85.54M | -88.33M | -91.74M | -90.90M |
| Capital Expenditure | -388.00K | -519.00K | -793.00K | -813.00K | -808.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -41.50M | -47.06M | -15.24M | 54.13M | 97.68M |
| Cash from Investing | -41.89M | -47.58M | -16.04M | 53.32M | 96.88M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 120.12M | 120.12M | 120.12M | 120.37M | 489.00K |
| Repurchase of Common Stock | -116.00K | -116.00K | -116.00K | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -76.00K | -182.00K | -420.00K | -420.00K |
| Cash from Financing | 120.00M | 119.93M | 119.83M | 119.95M | 69.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -14.35M | -13.19M | 15.46M | 81.53M | 6.04M |